Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran.
Curr Drug Targets. 2019;20(7):789-798. doi: 10.2174/1389450120666190123141553.
Prostate cancer is malignant cancer leading to high mortality in the male population. The existence of suppressive cells referred to as tumor-associated macrophages (TAM) is a major obstacle in prostate cancer immunotherapy. TAMs contribute to the immunosuppressive microenvironment that promotes tumor growth and metastasis. In fact, they are main regulators of the complicated interactions between tumor and surrounding microenvironment. M2 macrophages, as a type of TAMs, are involved in the growth and progression of prostate cancer. Recently, they have gained remarkable importance as therapeutic candidates for solid tumors. In this review, we will discuss the roles of M2 macrophages and worth of their potential targeting in prostate cancer treatment. In the following, we will introduce important factors resulting in M2 macrophage promotion and also experimental therapeutic agents that may cause the inhibition of prostate cancer tumor growth.
前列腺癌是导致男性人群死亡率较高的恶性肿瘤。抑制性细胞的存在，即肿瘤相关巨噬细胞（TAM），是前列腺癌免疫治疗的主要障碍。TAMs 有助于促进肿瘤生长和转移的免疫抑制微环境。事实上，它们是肿瘤与周围微环境之间复杂相互作用的主要调节者。M2 巨噬细胞作为 TAMs 的一种类型，参与了前列腺癌的生长和进展。最近，它们作为实体瘤治疗的候选药物引起了人们的极大关注。在这篇综述中，我们将讨论 M2 巨噬细胞的作用及其在前列腺癌治疗中的潜在靶向价值。接下来，我们将介绍导致 M2 巨噬细胞促进的重要因素，以及可能导致前列腺癌肿瘤生长抑制的实验治疗药物。
